Histamine H4 Receptor Expression in Triple-negative Breast Cancer: An Exploratory Study

Speisky, Daniela; Delgado, Mònica; Iotti, Alejandro; Nicoud, Melisa Beatriz; Ospital, Ignacio A.; Vigovich, Félix; Dezanzo, Pablo; Ernst, Glenda; Uriburu, Juan L; Medina, Vanina Araceli

doi:10.1369/00221554221083670

Cited by 8 publications

(3 citation statements)

References 99 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Speisky et al reported that the H4 receptor may be a useful biomarker for predicting triple negative breast cancer prognosis [ 92 ]. Based on data from the Cancer Genome Atlas, they observed that the H4 receptor is downregulated in basal-like/triple negative breast cancer compared with luminal A and normal breast-like tumors.…”

Section: Introductionmentioning

confidence: 99%

Breast cancer and neurotransmitters: emerging insights on mechanisms and therapeutic directions

et al. 2023

View full text Add to dashboard Cite

Exploring the relationship between various neurotransmitters and breast cancer cell growth has revealed their likely centrality to improving breast cancer treatment. Neurotransmitters play a key role in breast cancer biology through their effects on the cell cycle, epithelial mesenchymal transition, angiogenesis, inflammation, the tumor microenvironment and other pathways. Neurotransmitters and their receptors are vital to the initiation, progression and drug resistance of cancer and progress in our biological understanding may point the way to lower-cost and lower-risk antitumor therapeutic strategies. This review discusses multiple neurotransmitters in the context of breast cancer. It also discusses risk factors, repurposing of pharmaceuticals impacting neurotransmitter pathways, and the opportunity for better integrated models that encompass exercise, the intestinal microbiome, and other non-pharmacologic considerations. Neurotransmitters’ role in breast cancer should no longer be ignored; it may appear to complicate the molecular picture but the ubiquity of neurotransmitters and their wide-ranging impacts provide an organizing framework upon which further understanding and progress against breast cancer can be based.

show abstract

Section: Introductionmentioning

confidence: 99%

Breast cancer and neurotransmitters: emerging insights on mechanisms and therapeutic directions

et al. 2023

View full text Add to dashboard Cite

show abstract

“…Its increased expression correlated with increased patient survival. It is important to emphasise that there are no specific markers in TNBC at this time [40]. During the study, mice lacking the H4R receptor had significantly less tumour growth and percentage of CD4+ tumour-infiltrating T cells.…”

Section: Correlation Between Histamine Receptors and Breast Cancermentioning

confidence: 95%

Targeted therapy with histamine antagonists - New challenges to fight with breast cancer

Więsyk

Paulina

Chilimoniuk

et al. 2022

J Educ Health Sport

View full text Add to dashboard Cite

Breast cancer (BC) is currently the most commonly diagnosed cancer in women. BC is most often derived from the epithelial tissue of the mammary gland and is a global problem due to the steady increase in morbidity and mortality in most countries. A particular problem today is the triple negative subtype (TNBC), which accounts for approximately 10-15% of breast cancer cases. BC occurs most frequently in young women and is characterised by various biological characteristics, an unfavourable clinical course and a poor prognosis. Recent studies to detect the effects of histamine receptors on breast cancer have shown that all H1R-H4R receptors are also hyperactive in the cancer microenvironment. Chronically maintaining a high level of histamine in the tumour-affected tissue contributes to increased angiogenesis at this site, induction of cancer cells proliferation and T lymphocyte dysfunction. The rising incidence of breast cancer is contributing to an increasing amount of research into targeted therapies. Studies on the effect of histamine antagonists through H1R-H4R receptors have proven their effectiveness in the treatment of breast cancer. Among those in the study, there was a reduction in tumour growth, cell proliferation and an increase in apoptosis. The use of histamine antagonists also contributed to a reduced risk of death from breast cancer and increased overall survival (OS). Therefore, targeted therapy is needed to improve the prognosis of patients with breast cancer.

show abstract

“…Moreover, histamine has reduced cell proliferation in a dose-dependent manner, by inducing cell apoptosis and senescence at a micromolar concentration through the activation of the histamine H4 receptor (H4R) in human MDA-MB-231 and murine 4T1 TNBC cells [ 15 , 16 , 17 ]. Furthermore, the expression of the four histamine receptors subtypes have been described in human BC cell lines and tumor samples [ 18 , 19 , 20 , 21 ]. Preclinical data show that histamine improved conventional antitumor therapies response in different cancer types, supporting the rationale for the use of a combination therapy with histamine.…”

Section: Introductionmentioning

confidence: 99%

Nanomicellar Formulations Loaded with Histamine and Paclitaxel as a New Strategy to Improve Chemotherapy for Breast Cancer

Nicoud

Ospital

Delgado

et al. 2023

IJMS

Self Cite

View full text Add to dashboard Cite

Triple negative breast cancer (TNBC) is the most aggressive breast cancer subtype. Currently, paclitaxel (PTX) represents the first-line therapy for TNBC; however it presents a hydrophobic behavior and produces severe adverse effects. The aim of this work is to improve the therapeutic index of PTX through the design and characterization of novel nanomicellar polymeric formulations composed of a biocompatible copolymer Soluplus® (S), surface-decorated with glucose (GS), and co-loaded either with histamine (HA, 5 mg/mL) and/or PTX (4 mg/mL). Their micellar size, evaluated by dynamic light scattering, showed a hydrodynamic diameter between 70 and 90 nm for loaded nanoformulations with a unimodal size distribution. Cytotoxicity and apoptosis assays were performed to assess their efficacy in vitro in human MDA-MB-231 and murine 4T1 TNBC cells rendering optimal antitumor efficacy in both cell lines for the nanoformulations with both drugs. In a model of TNBC developed in BALB/c mice with 4T1 cells, we found that all loaded micellar systems reduced tumor volume and that both HA and HA-PTX-loaded SG micelles reduced tumor weight and neovascularization compared with the empty micelles. We conclude that HA-PTX co-loaded micelles in addition to HA-loaded formulations present promising potential as nano-drug delivery systems for cancer chemotherapy.

show abstract

Histamine H4 Receptor Expression in Triple-negative Breast Cancer: An Exploratory Study

Cited by 8 publications

References 99 publications

Breast cancer and neurotransmitters: emerging insights on mechanisms and therapeutic directions

Breast cancer and neurotransmitters: emerging insights on mechanisms and therapeutic directions

Targeted therapy with histamine antagonists - New challenges to fight with breast cancer

Nanomicellar Formulations Loaded with Histamine and Paclitaxel as a New Strategy to Improve Chemotherapy for Breast Cancer

Contact Info

Product

Resources

About